Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Anika Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Anika Therapeutics, Inc.

ANIK

Anika Therapeutics, Inc.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. develops and manufactures hyaluronic acid (HA)-based medical products focused on osteoarthritis (OA) pain management and regenerative orthopedic solutions. Its key offerings include viscosupplements like Monovisc and Orthovisc, and regenerative products such as the Integrity Implant System and Hyalofast scaffold. Serving global markets through direct sales and distributor networks, Anika targets clinicians and surgeons with innovative, clinically supported therapies designed to improve patient outcomes in early intervention orthopedics.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Anika Therapeutics, Inc.

1
1
Anika Therapeutics, Inc. Anika Therapeutics Reports $29.6 Million Revenue in Q1 2026, 13% Increase Year-Over-Year

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Anika Therapeutics, Inc. Anika Therapeutics Reports $112.8 Million Revenue for Fiscal Year 2025, Net Loss Improves to $10.9 Million

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Anika Therapeutics, Inc. Anika Therapeutics Reports $27.8 Million Revenue in Q3 2025, Down 6% Year-Over-Year

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Anika Therapeutics, Inc. Anika Therapeutics Reports Decline in Q2 2025 Revenue and Increased Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Anika Therapeutics, Inc. Anika Therapeutics Reports $26.2 Million Revenue in Q1 2025, 10% Decrease from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Anika Therapeutics, Inc. Anika Therapeutics Reports $119.9 Million Revenue for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Anika Therapeutics, Inc. Anika Therapeutics Reports Decline in Revenue and Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments